haematology
Sickle Cell Crisis
Vaso-occlusive crisis and acute chest syndrome management in sickle cell disease
Source: BSH 2021 / BCSH
Step 1 of ~7
info
Sickle Cell Crisis
Vaso-occlusive (painful) crisis is most common. Acute chest syndrome is most common cause of death. Assess: pain score, O2 saturation, chest symptoms, temperature.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Hydroxycarbamide (Hydroxyurea) · Cytoreductive agent / Sickle cell disease / CML
- Crizanlizumab · P-selectin Inhibitor — Sickle Cell Disease
- Voxelotor · Haemoglobin S Polymerisation Inhibitor — Sickle Cell Disease
- Inebilizumab (Anti-CD19 — IgG4-Related Disease) · Anti-CD19 Monoclonal Antibody (B-Cell Depleting)
- Ianalumab (Anti-BAFF — Primary Sjögren's Syndrome) · Anti-BAFF Monoclonal Antibody (B-Cell Survival Factor Inhibitor)
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
- Anticoagulation Reversal · BSH 2016 / ESC
- Blood Transfusion — Indications and Safety · BSH 2012 / NICE
Decision support only. Always apply local guidelines and clinical judgement.